帕唑帕尼治疗扩增型子宫癌肉瘤的疗效：一例报告。
Efficacy of pazopanib in -amplified uterine carcinosarcoma: A case report.
作者信息
Sawayama Saki, Murakami Ryusuke, Aki Megumi, Kawaguchi Yusuke, Takao Yumi, Nonogaki Hirofumi, Goto Tomoyuki, Yamauchi Chikako
机构信息
Department of Obstetrics and Gynecology, Shiga General Hospital, Moriyama, Shiga, Japan.
Department of Gynecology, Minamikusatsu Health Examination Centre, Kusatsu, Shiga, Japan.
出版信息
Gynecol Oncol Rep. 2022 May 2;41:100993. doi: 10.1016/j.gore.2022.100993. eCollection 2022 Jun.
•We reported the use of pazopanib in the treatment of recurrent uterine carcinosarcoma with amplification.•The expert tumor board recommended pazopanib for off-label use based on genetic mutations found in cancer gene panels.•Pazopanib, a multi-tyrosine kinase inhibitor, was effective against recurrent uterine sarcoma with amplification.•Pazopanib maintained the patient's quality of life for a certain period.
•我们报告了帕唑帕尼在治疗伴有扩增的复发性子宫癌肉瘤中的应用。
•专家肿瘤委员会根据癌症基因检测板中发现的基因突变，推荐帕唑帕尼用于非标签用药。
•帕唑帕尼是一种多酪氨酸激酶抑制剂，对伴有扩增的复发性子宫肉瘤有效。
•帕唑帕尼在一定时期内维持了患者的生活质量。
Zotero 插件